MiR-25 exerts a cardioprotective effect in a rat model of myocardial ischaemia-reperfusion injury by targeting HMGB1.
We previously confirmed the targeting of high-mobility group box 1 (HMGB1) by miR-25. This project aims to further investigate whether miR-25 improves myocardial ischaemia-reperfusion injury (IRI) in vivo by targeting HMGB1. A rat model of myocardial IRI was established by the ligation of the left anterior descending (LAD) coronary artery for 45 min followed by 2 h, 4 h or 6 h reperfusion. The expression of miR-25, HMGB1, and apoptosis-related proteins in the myocardium were determined by quantitative real-time PCR (qRT-PCR) and western blotting. The activities of myocardial enzymes and the release of inflammatory cytokines were evaluated by enzyme-linked immunosorbent assay (ELISA). Evans blue/triphenyltetrazolium chloride (TTC) double staining was performed to assess infarct size. Myocardial apoptosis was detected by terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) staining. MiR-25 expression was significantly downregulated, while HMGB1 was highly expressed at the mRNA and protein levels in myocardial tissues after induction of the IRI model. MiR-25 agomir administration suppressed the expression of HMGB1 in myocardial tissues. Furthermore, administration of both miR-25 agomir and LV-sh HMGB1 resulted in reduced serum myocardial enzyme activities, cytokine secretion, and myocardial apoptosis during myocardial IRI. MiR-25 mitigated myocardial IRI-induced damage by targeting HMGB1.